This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use

 
 

27Feb

Accelerating Cancer Drug Development - From target to patients

Location: Alderley Park Conference Centre, Alderley Park, Cheshire


Focusing upon the strengths in the discovery, development and manufacture of cancer medicines in the North of England through to commercialisation (patients), this event will highlight industry, academic and clinical strengths whilst showcasing key activities, infrastructure and the joined up translational environment which exists in the North.

We are delighted to have Susan Galbraith, Vice President of Oncology at AstraZeneca and Rob Bristow, Director of MCRC and Chief Academic Officer at The Christie NHS Foundation Trust as Keynote Speakers.

Conference Programme

Time

Session

Speakers

08.30 - 09.00

Arrival and Registration


09.00 - 09.05

Welcome Address

09.05 - 09.35

Keynote Speaker

Susan Galbraith, Vice Presdient - Oncology, AstraZeneca

09.35 - 11.05

Parallel Sessions
New Target Identification & Chemistry

Chair: Tilly Bingham, Redx Pharma

Allan Jordan, Head of Chemistry, CRUK
Cliff Jones, Head of Chemistry, Redx Pharma
Thomas Pesnot, Group Leader (Medicinal Chemistry) Concept Life Sciences
Caroline Springer, Director of Drug Discovery, CRUK

 

09.35 - 11.05

Parallel Sessions
Preclinical: PK ADME, Toxicology

Richard Knight, Director, ApconiX
Simon Barry, Senior Principal Scientist, AstraZeneca
Peter Simpson, Chief Scientific Officer, Medicines Discovery Catapult
Juliana Maynard, Head of Imaging Services Alderley Imaging, Alderley Park

11.05 - 11.35

Coffee, Networking & Exhibition

11.35 - 12.20

Clinical Trials and How Clinical Decisions are Made

Glen Clack, Honorary Professor of Translational Medicine, University of Sheffield
Matthew Krebs, Clinical Senior Lecturer in Experimental Cancer Medicine, The Christie

12.20 - 12.40

Patients Perspective

TBC

12.40 - 13.50

Lunch, Networking & Exhibition

13.50 - 14.20

Keynote Speaker

Rob Bristow, Director MCRC and Chief Academic Officer The Christie

14.20 - 15.35

Parallel Sessions
Pharmaceutical Development

Chair: Paul Dickinson, Seda Pharmaceutical Development Solutions

Paul Stott, Vice President Global Product Development, AstraZeneca
Mike Frodsham, Pharmaceutical Development Officer, Quay Pharma
Marianne Ashford, Principal Scientist,  AstraZeneca

14.20 - 15.35  

Parallel Sessions
Moving Towards an Era of Personalised
Medicine

Caroline Dive, Deputy Director, CRUK
Angela Silmon, Chief Executive Officer, NewGene

15.35 - 16.45

Panel Discussion
Effect of Industrial and Life
Science Strategies on Cancer Research 

Rob Bristow, Director MCRC and Chief Academic Officer The Christie
Peter Simpson, Chief Scientific Officer, Medicines Discovery Catapult

16.45

Close

 

Delegate Fees
Premium Member: £125.00 + VAT
Member: £155.00 + VAT
Non-Member: £250.00 + VAT

If you are interested in exhibiting at the event, please contact Helen Williams at helen.williams@bionow.co.uk for further information.

> Register here